CA-TRIVVER
14.5.2018 10:02:10 CEST | Business Wire | Press release
Trivver , the premiere advertising exchange for Extended Reality (XR) environments including 3D, virtual reality, mixed reality and augmented reality, today announced that it will launch the sale of up to 100 million Trivver Tokens (TRVR) to accelerate the adoption, commercialization and monetization of XR technology across devices and industries for all stakeholders in the ecosystem – including content publishers, advertisers, brands, agencies and consumers.
Current 2D advertising tactics like pop-ups, banners, video and interstitials are highly disruptive to immersive XR experiences, leading to limited advertiser adoption of XR and reduced monetization opportunities for XR developers and publishers. Placing ads organically within the natural settings of XR environments is the answer, but the current processes that developers, publishers and advertisers use to execute this strategy is tedious and costly, as ads and objects need to be manually resized to fit each unique location. With Trivver’s suite of patented technology, including its core Smart Object Technology, developers are able to create and deliver native advertising directly into XR environments. This approach enables advertisers to create contextual, integrated XR ad campaigns to engage consumers in a unique and impactful way and gives publishers the opportunity to efficiently monetize their XR content.
“We believe in the exponential possibilities of XR and in the profound, lasting and global impact of this technology,” said Joel LaMontagne, CEO of Trivver. “We are passionate about driving XR adoption among consumers and within the enterprise. Our goal is to enable publishers and developers in the XR space to fund themselves through advertising and encourage the improvement of technology that enhances XR experiences for consumers. We’re also making it easier for advertisers to promote their brand in the XR space through seamless product placement – delivering relevant and interesting content to engage their users.”
In order to drive XR adoption and momentum, Trivver launched its pre-sale of TRVR tokens, which can be purchased with a bonus until June 5, 2018. The public token sale begins on June 8, 2018 and will close on July 7, 2018. The public sale will aim to raise $35 million, with the pre-sale accounting for up to $5 million.
Token Sale Details:
- Under the terms of the sale, 1 ETH is equivalent to 750 TRVR (1 TRVR ~ 0.00133 ETH) and a hard cap of 100 million TRVR tokens are available for purchase of the finite supply of 200 million total TRVR.
- All available TRVR will be issued during the distribution period, of which, 50 percent will be allocated to the public and 50 percent will be allocated to the reserve to be held by the company and used to stimulate growth in the Trivver XR advertising ecosystem by rewarding participants with TRVR.
- All TRVR not distributed will be burned.
TRVR is the currency for the Smart Object Economy. Trivver’s patented Branded Smart Objects (BSOs) are 3D objects with product information (SKU data, coupons, social media links etc.) that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment. Trivver’s BSOs send valuable viewability and user engagement metrics back to the advertiser that will result in the best ROI.
Trivver launched its token sale in order to accelerate the build out of its Smart Objects catalog and will incentivize developers to participate through a system of rewards and payments of TRVR. Developers can earn TRVR for building and adding smart objects to the catalog. They can also use TRVR to list the smart object in Trivver’s inventory and establish authorship of the object. As the author, developers will receive royalties paid in USD from Trivver whenever revenues are generated by the smart object - from a publisher using it to build XR content or by an advertiser using it for future XR ad campaigns.
The Trivver platform is currently in beta and the company has already seen significant interest, announcing upcoming pilot programs in collaboration with WayFair and Cannon.
To learn more about Trivver and to participate in the token sale, visit: https://www.trivver.com/tokensale or join the conversation on Telegram to speak directly with the project’s founders and developers: https://t.me/trivvertokensale . Download the token sale whitepaper at: https://www.trivver.com/docs/Trivver_Whitepaper.pdf .
About Trivver
Trivver is the premiere advertising exchange for Extended Reality (XR) environments – 3D, virtual reality, mixed reality and augmented reality. The Trivver platform makes creating and deploying 3D interactive branded objects easier, allowing brands to programmatically execute targeted, impactful and scalable XR campaigns.
Trivver’s revolutionary, patented Branded Smart Objects (BSOs) are 3D objects that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment.
The Trivver XR Ad Exchange (XRAE) is a programmatic solution that lets advertisers create, run and monitor a highly targeted XR ad campaign in near real time, on mobile apps and desktop applications. Trivver enables publishers to monetize XR environments with branded content that is native and organic – eliminating pop-ups, banners and interstitials that are disruptive to user experience. The Trivver platform facilitates an organic relationship between brand and consumer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514005068/en/
Contact:
Affect
Nicole Sullivan, 212-398-9680
trivver@affect.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
